Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188772 | 0.94 | HPGD (0.41) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL22657953 | 0.93 | HPGD (0.44) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL20265001 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL2600436 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL360939 | 0.78 | — | — | |
| SCHEMBL31552232 | 0.77 | HPGD (0.40) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL31551926 | 0.75 | HPGD (0.42) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL360446 | 0.74 | TSHR (0.40) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1601359 | 0.73 | USP2 (0.42) | USP2SMN1; SMN2CTSKESR2NR1H2 | |
| SCHEMBL4552377 | 0.73 | USP2 (0.39) | USP2SMN1; SMN2CTSKESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117945995-A | Alkylated nitrogen-containing heterocyclic compound and preparation method and application thereof | 中国科学院青海盐湖研究所 | 2024-04-30 | — | — | CN | claimed |
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | claimed |
| EP-3004120-B1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | UNIV NANYANG TECH (SG) | 2018-08-29 | — | — | EP | claimed |
| CN-105658656-A | 1, 1' -spiroindane-7, 7-bisphosphine oxides as highly active supporting ligands in palladium-catalyzed asymmetric Heck reactions | 南洋理工大学 | 2016-06-08 | — | — | CN | claimed |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-19 | — | — | US | claimed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | claimed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2005021533-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | AMGEN INC. | 2005-03-03 | — | — | US | claimed |
| US-6825236-B2 | ACTIVE AGAINST TUMORS IN MICE AND ARE GENERALLY WELL TOLERATED | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | claimed |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-10-14 | — | — | US | claimed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | claimed |
| EP-0266950-B1 | Nor-statine and nor-cyclostatine polypeptides | PFIZER (US) | 1993-12-29 | — | — | EP | claimed |
| EP-0473337-A2 | Nor-statine and nor-cyclostatine polypeptides in the treatment of ocular hypertension and glaucoma | PFIZER INC. (US) | 1992-03-04 | — | — | EP | claimed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | claimed |
| EP-0310918-A2 | Peptide-like amino-acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | claimed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | SBK1, SIK1, PDPK1 | USP2 4842/4885SMN1; SMN2 4202/4885CTSK 352/4885 |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | NQO1, NQO2, UGT1A1 | USP2 3098/4885SMN1; SMN2 2647/4885CTSK 1373/4885 |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, NAP1L4 | USP2 4562/4885SMN1; SMN2 1941/4885CTSK 3433/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | USP2 1290/4885SMN1; SMN2 1335/4885CTSK 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.